mRNA-based Personalized Cancer Vaccine mRNA-4157
Moderna and Merck Report Sustained 49% Risk Reduction in Recurrence or Death with mRNA-Keytruda Combo at Five Years in Melanoma Trial
Moderna; Merck; Keytruda; intisemeran autogene; mRNA-4157; melanoma; recurrence-free survival; Phase 2b